ホームOPL • ASX
add
Opyl Ltd
市場ニュース
財務情報
損益計算書
収益
純利益
| (AUD) | 2024年12月info | 前年比変化率 |
|---|---|---|
収益 | 16.77万 | 37.65% |
営業費用 | 32.34万 | 42.41% |
純利益 | -34.16万 | 46.47% |
純利益率 | -203.67 | 61.11% |
1 株当たりの収益 | — | — |
EBITDA | -31.80万 | 25.38% |
実効税率 | — | — |
貸借対照表
総資産
負債総額
| (AUD) | 2024年12月info | 前年比変化率 |
|---|---|---|
現金および短期投資 | 32.95万 | -43.64% |
総資産 | 38.48万 | -41.63% |
負債総額 | 69.58万 | -3.76% |
純資産 | -31.10万 | — |
発行済み株式 | 1.71億 | — |
帳簿価格 | ∞ | — |
総資産利益率 | -208.46% | — |
資本利益率 | -683.20% | — |
キャッシュ フロー
現金の純増減額
| (AUD) | 2024年12月info | 前年比変化率 |
|---|---|---|
純利益 | -34.16万 | 46.47% |
営業キャッシュ フロー | -31.00万 | -6.88% |
投資キャッシュ フロー | -662.00 | — |
財務キャッシュ フロー | 28.81万 | -19.06% |
現金の純増減額 | -2.25万 | -134.21% |
フリー キャッシュ フロー | -20.07万 | 18.01% |
概要
Opyl is a Melbourne-based company listed on the Australian Securities Exchange that applies artificial intelligence to improving clinical trial efficiencies. The company has two key platforms: Opin a global clinical trial recruitment platform and service as well as TrialKey a Saas software as a service platform that predicts and designs optimized clinical trial protocols, reducing the risk of failure and improving a return on investment in new and emerging medicines, devices, and diagnostics..
Opyl is a rebrand and strategic realignment from a former company known as ShareRoot, a US-based martech platform that secured rights to user-generated content on social media, predominantly used by big brands that collaborated with influencers.
Before going public in 2016, ShareRoot had previously participated in 500 Startups batch 8 and raised a round of angel investing.
ShareRoot was rebranded to Opyl in 2020 to work on technology to support the health and life sciences sector. Wikipedia
設立
2013
ウェブサイト
従業員数
3
